• Publications
  • Influence
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
It is recommended that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation. Expand
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients. Expand
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
Combination treatment of inhaled long-acting beta2 agonists and corticosteroid combination treatment produces better control of symptoms and lung function, with no greater risk of side-effects than that with use of either component alone, and should be considered for patients with COPD. Expand
Chronic obstructive pulmonary disease phenotypes: the future of COPD.
Significant heterogeneity of clinical presentation and disease progression exists within chronic obstructive pulmonary disease (COPD). Although FEV(1) inadequately describes this heterogeneity, aExpand
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression. Expand
Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire.
The SGRQ-C contains the best of the original items, no longer specifies a recall period, and produces scores equivalent to the original. Expand
St. George's Respiratory Questionnaire: MCID
Estimates of MCID should be used as indicative values of clinical significance, and methods of analysing clinical trial results should reflect this, and use appropriate statistical tests for comparison with the MCID. Expand
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
In the TORCH study, SFC reduced moderate-to-severe exacerbations and improved health status and FEV1 across GOLD stages, and is an effective treatment option for patients with GOLD stage II COPD. Expand
Treatable traits: toward precision medicine of chronic airway diseases
This Perspective proposes a precision medicine strategy for chronic airway diseases in general, and asthma and COPD in particular, and a discussion of the concept of “treatable traits” as a way towards precision medicine of chronicAirway diseases. Expand
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised
Both aclidinium/formoterol BID doses significantly improved bronchodilation versus monotherapy, and dyspnoea versus placebo, with no increase in safety risk. Expand